Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 5—May 2007

Dispatch

Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK

J. A. Chris Delaney*, Sandra Dial*, Alan Barkun*, and Samy Suissa*Comments to Author 
Author affiliations: *McGill University Health Center, Montreal, Canada;

Main Article

Table 2

Most recent prescription for any antimicrobial drug and effect of proximity on risk of acquiring Clostridium difficile–associated disease, UK, 1993–2004*

Exposure to antimicrobial drug Case-patients, n = 1,233 (%) Control-patients, n = 12,330 Crude OR Adjusted OR (95% CI)†
None (reference) 379 (30) 6,449 (52) 1.0 1.0 (reference)
Most recent prescription‡
  1–90 d (current) 456 (37) 1,649 (13) 5.0 3.7 (3.1–4.4)
  91–180 d 128 (10%) 1067 (9) 2.2 1.8 (1.4–2.3)
  181–365 d 131 (11) 1,498 (12) 1.6 1.3 (1.0–1.6)
  1–2 y 139 (11) 1,674 (13) 1.5 1.3 (1.0–1.6)
Most recent fluoroquinolone prescription†
  1 – 90 d (current) 70 (5.7) 84 (0.7) 10.9 6.2 (4.4–8.8)
  91–180 d 12 (1.0) 70 (0.6) 1.7 1.2 (0.6–2.3)
  181–365 d 27 (2.2) 114 (0.9) 2.4 1.7 (1.1–2.7)
  1–2 y 36 (2.9) 198 (1.6) 1.9 1.3 (0.9– 2.0)

*OR, odds ratio; CI, confidence interval.
†Adjusted for inflammatory bowel disease, diverticular disease, peptic ulcer disease and gastroesophageal reflux disease,
Helicobacter pylori–associated disease, pernicious anemia, cancer including solid tumor and hematologic malignancies, diabetes
mellitus, chronic obstructive pulmonary disease, cirrhosis, nonsteroidal anti-inflammatory agents, aspirin, H2 blockers, proton pump
inhibitors, and antimicrobial use in the past 2 years.
‡2 y before the index date.

Main Article

TOP